



OncoSpan is a well-characterized, cell line-derived Reference Standard containing over 380 variants across 152 key cancer genes. Variants are present between 1-100% allelic frequency (AF), with 47 variants present at ≤ 20% AF for LOD determination of your assay. Every batch of OncoSpan DNA has 25 variants confirmed by ddPCR, in addition to being fully exome sequenced (Batches before 57404 were sequenced at 500x coverage on an Illumina platform using the Agilent SureSelect Human All Exon V6 kit. Batches from 57404 are sequenced at 500x coverage by Revvity Omics using the Agilent CREV3 kit and an Illumina platform). This provides you with an accurate and reliable truth set for comparison to your assay’s performance. You will receive a password upon ordering to download the raw NGS data for your batch (bam, bed and vcf files). Alternatively, for your convenience we have also listed the 386 high confidence variants in an easy-to-access excel document that can be downloaded.
Technical Data
Format: Cell-free DNA
Genes Covered: ABL1, AKT1, AKT2, ALK, APC, AR, ARID1A, ATR, ATRX, AXL, BARD1, BCL6, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BTK, BUB1B, CARD11, CCND1, CCND3, CCNE1, CD79B, CDh2, CDK12, CDK4, CEP57, CFH, CREBBP, CSF1R, CTNNB1, DDR2, DIS3L2, DNMT3A, EGFR, EML4, EP300, EPCAM, ERBB2, ERBB3, ERCC1, ERCC2, ERCC4, ERCC5, ERG, ETS1, ETV4, EWSR1, EXT1, FANCA, FANCD2, FANCE, FANCG, FANCI, FANCM, FBXW7, FGF10, FGF2, FGF3, FGF6, FGFR1, FGFR3, FLCN, FLI1, FLT1, FLT3, FZR1, GATA2, GATA3, GEN1, GNA11, GNAS, HNF1A, HRAS, IDh2, IDh4, JAK1, JAK2, JAK3, KDR, KIT, KRAS, LDLR, MAGI1, MAP2K1, MAP2K2, MAX, MDM4, MED12, MET, MLh2, MLLT3, MMAB, MRE11, MSh4, MSH6, MTOR, NBN, NF1, NFE2L2, NOTCh1, NOTCh4, NOTCh6, NRAS, NRG1, NTRK1, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PMS2, PPARG, PPP2R2A, PRKAR1A, PROC, PTCh2, PTPN11, RAD51B, RAD54L, RAF1, RB1, RBM45, RECQL4, RET, RHBDF2, ROS1, RPS6KB1, SDHB, SF3B1, SF3B2, SLTM, SLX4, SMARCB1, SMO, SMOX, STK11, TERT, TET2, TFRC, TP53, TP53BP1, TSC1, TSC2, WRN, XPA, XPC, ZNF395
Allelic Frequencies: 1% - 92.5% for ddPCR-verified variants
Buffer: Tris-EDTA (10mM Tris-HCl, 1mM EDTA), pH 8.0
Product Information
Verified Mutations:
Chromosome | Gene | Variant | Expected Allelic Frequency % |
---|---|---|---|
chr2 (29416025) | ALK | N/A (Ins) | 10.0% |
chr5 (112175770) | APC | p.T1493T | 35.0% |
chr7 (140453136) | BRAF | p.V600E | 10.5% |
chr13 (32913558) | BRCA2 | p.K1691fs*15 | 32.5% |
chr3 (41266101) | CTNNB1 | p.S33Y | 32.5% |
chr3 (41266133) | CTNNB1 | p.S45del | 10.0% |
chr7 (55241707) | EGFR | p.G719S | 24.5% |
chr7 (55249071) | EGFR | p.T790M | 1.0% |
chr7 (55259515) | EGFR | p.L858R | 3.0% |
chr7 (55242464) | EGFR | p.E746_A750 delELREA | 2.0% |
chr7 (55249063) | EGFR | p.Q787Q | 15.0% |
chr4 (153244155) | FBXW7 | p.S668fs*39 | 32.5% |
chr13 (28578214) | FLT3 | p.P986fs*>8 | 10.0% |
chr4 (55599321) | KIT | p.D816V | 10.0% |
chr4 (55602765) | KIT | p.L862L | 7.5% |
chr12 (25398281) | KRAS | p.G13D | 15.0% |
chr12 (25398284) | KRAS | p.G12D | 6.0% |
chr7 (116436022) | MET | p.A1357A | 7.0% |
chr7 (116339847) | MET | p.L238fs*25 | 7.0% |
chr9 (139409754) | NOTCh1 | p.P668S | 30.0% |
chr1 (115256530) | NRAS | p.Q61K | 12.5% |
chr3 (178936091) | PIK3CA | p.E545K | 9.0% |
chr3 (178952085) | PIK3CA | p.H1047R | 17.5% |
chr10 (43613843) | RET | p.L769L | 60.0% |
chr17 (7579472) | TP53 | p.P72R | 92.5% |
Unit Size: 350 ng
Concentration: 20 ng/µl
Storage: 4˚C
Expiry: See all product shelf life information
Quality Control
Allelic Frequency: Droplet Digital PCR™
Genotype: Next Generation Sequencing
Quality: Tapestation
Quantification: Qubit dsDNA BR Assay (post-fragmentation)
Intended use: For assay developers and molecular diagnostic labs for routine performance monitoring of molecular biology assays. Research use only. Not for diagnostic procedures.
OncoSpan publications
Read these research articles citing the use of OncoSpan reference standards.
- Validation of a pan-cancer targeted next generation sequencing panel in New Zealand | New Zealand Journal of Medical Laboratory Science
- Enabling variant calling in challenging FFPE samples by coupling a novel library preparation chemistry with exome sequencing | Journal of Clinical Oncology
- Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel | Journal of Clinical Pathology
- Performance Analysis of Three Bioinformatic Variant Callers Using a Somatic Reference Standard | Children's Mercy Kansas City